ProCE Banner Activity

Updates on Pneumococcal Vaccines: My Take on the Latest IDWEEK 2021 Data

Clinical Thought
Studies at IDWeek 2021 show that pneumococcal vaccines with increased serotype valency are safe and efficacious in both children and adults. Here is my take on how these studies could affect my practice and the current vaccination guidelines.

Released: November 19, 2021

Expiration: November 18, 2022

Share

Faculty

Paul G. Auwaerter

Paul G. Auwaerter, MD

Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Paul G. Auwaerter, MD

Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Paul Auwaerter, MD, MBA, has disclosed that he has received consulting fees from Adaptive Biotherapeutics, EMD Serono, and Pfizer and funds for research support from Humanigen, MicroB-Plex, and Pfizer.